the leading light for human-on-a-chip Research
Hesperos is named for Venus in the evening sky. Like her, we are a leading light, providing world-class research in disease modeling and drug testing through our use of human-on-a-chip systems. Our patent positions and the over 20 years of expertise of both Drs. Shuler and Hickman make us the company to work with for your most difficult problems as well as for cost competitive, routine, human-on-a-chip assays.
The hesperos difference
Hesperos, Inc. brings together biologists, surface chemists, and engineers in order to produce some of the worlds most advanced organs-on-chips. From gene expression to electrophysiology, our biologists recreate key components of various organs. Chemically patterned microchips are engineered to enable real-time monitoring of organ activity. Finally, our engineers utilize sophisticated measurement techniques in order to detect and quantify minute changes. The result of this collaboration is an ability to study therapeutics in a way which was previously only possible in clinical trials.
Industries We Serve
Chemicals, Nutraceuticals, and Supplements
Hesperos Chief Scientist, Dr. James Hickman, awarded Researcher of the Year at the 2022 BioFlorida conference in Miami
In a recent study published in Biomaterials, a team of researchers led by Hesperos Chief Scientist Dr. J. Hickman established a significant finding to better understand ALS etiology and potential new treatment targets.
Read the Open Letter here We are proud to support this open letter to congress encouraging representatives to pass the FDA Modernization Act. Originally passed in 1938, the Federal Food, Drug, and Cosmetics Act (FFDCA) was … Read More
Financial Times wrote an excellent feature on microphysiological systems, highlighting Hesperos’ Human-on-a-Chip.
Hesperos Shows Potential for In Vitro Approach to Replace Conventional Animal Efficacy Studies for Rare Neuromuscular Disorders
1) Validates use of Human-on-a-Chip system to mimic disease mechanisms of rare autoimmune neuropathies that cannot be replicated in animal models.
2) Efficacy data from microphysiological system supported the authorization of a clinical study (NCT04658472) in 2021 through collaboration with Sanofi.
Hesperos Validates Utility of Human-on-a-Chip® Approach to Model Rare Autoimmune Disease, Myasthenia Gravis
Hesperos, Inc is proud to announce Dr. Virginia Smith’s recent publication in Frontiers in Cell and Developmental Biology which validates the Human-on-a-Chip method to model the rare autoimmune disease, Myasthenia Gravis. Read the full press release below: … Read More
Hesperos & Tabula Rasa Awarded $1.9M NIH Grant to investigate preventable Drug-induced Alzheimer’s Disease
Hesperos and Tabula Rasa receive $1.9M National Institutes of Health Research Grant Focused on Preventable Drug-Induced Alzheimer’s Disease
New study published in Nature Scientific Reports validates the utility of Human-on-a-Chip to model Nonalcoholic Fatty Liver Disease (NAFLD)
Senior Editor with Pharma Manufacturing interviews Hesperos executives Michael Shuler and Nathan Post on the rise of Human-on-a-Chip (HoaC) systems and how they are replacing the need for animal testing in drug discovery.
About Our Team
Hesperos, Inc, is a leader in efforts to characterize an individual’s biology with human-on-a-chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems which they coined "human-on-a-chip."